New Three-Drug cocktail aims to tackle tough leukemia

NCT ID NCT05657639

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a combination of three drugs—venetoclax, cladribine, and low-dose cytarabine—in 68 adults aged 16-70 with acute myeloid leukemia that has returned or not responded to prior treatment. The goal is to see if this cocktail can shrink or eliminate leukemia cells better than standard therapy. Participants are randomly assigned to receive either the new combo or a standard regimen.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Venetoclax, cladribine, and low-dose cytarabine (CAV regimen)
What this could lead to: If successful, this could offer a new treatment option for people with hard-to-treat acute myeloid leukemia that has come back or not responded to standard therapy.
What could go wrong: This is an early phase 2 trial with only 68 participants, so results may not apply to everyone. The combination may cause side effects like low blood counts or infections, and it may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

The First Affliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, 215006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.